A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways

The clinical introduction of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which targets B-cell antigen-receptor (BCR)-controlled integrin-mediated retention of malignant B cells in their growth-supportive lymphoid organ microenvironment, provided a major breakthrough in lymphoma and leuke...

Descripción completa

Detalles Bibliográficos
Autores principales: de Rooij, Martin F. M., Thus, Yvonne J., Swier, Nathalie, Beijersbergen, Roderick L., Pals, Steven T., Spaargaren, Marcel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018714/
https://www.ncbi.nlm.nih.gov/pubmed/35440579
http://dx.doi.org/10.1038/s41467-022-29835-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018714/
https://www.ncbi.nlm.nih.gov/pubmed/35440579
http://dx.doi.org/10.1038/s41467-022-29835-y

Ejemplares similares